Development of new AI algorithm could revolutionise drug discovery say researchers
Researchers from King’s College London and Imperial College London have developed an innovative AI algorithm that has the potential to significantly accelerate drug discovery. This computer-based tool, known as Drug Synthesis using Monte Carlo (DrugSynthMC), is designed to enhance the diversity of chemical structures within drug libraries, creating thousands of drug-like molecules in just seconds.
Revolutionising Drug Discovery with AI
DrugSynthMC aims to overcome one of the major challenges in drug discovery: the limitations of existing drug libraries. These libraries often contain compounds that have been extensively studied and catalogued, leaving little room for the exploration of novel molecules. The new algorithm addresses this issue by generating a vast array of chemically diverse compounds, opening up new possibilities for drug candidates that may have previously been overlooked.
Dr Filippo Prischi, senior lecturer in molecular biochemistry at King’s College London and co-senior author of the study, highlighted the breakthrough:
“We showed that DrugSynthMC can expand the chemical diversity of compounds in available libraries, overcoming the limitations of existing drug collections.”
This capability is crucial because virtual-library screening—a process that relies on computational tools to sift through vast databases of known compounds—is a vital step in early-stage drug discovery. The objective is to identify chemical structures that have a high probability of binding to specific drug targets. Once promising compounds are identified, they undergo optimisation and testing in laboratory settings, both in cell cultures and animal models, before advancing to clinical trials.
Breaking Free from Traditional Limitations
Traditional methods of virtual-library screening are confined to compounds already known and catalogued. This limitation restricts researchers from discovering truly novel chemical entities, which could offer fresh approaches to treating diseases. DrugSynthMC breaks free from these constraints, allowing for the generation of new, previously unconsidered molecules.
At its core, the AI algorithm utilises a technique called Monte Carlo Tree Search, a mathematical method that calculates possible outcomes based on predefined actions. This sophisticated approach allows the algorithm to systematically build chemical structures in a simple text format. It follows a set of instructions designed to maximise the key properties of orally available drugs, such as solubility, synthesis feasibility, and safety.
Success in Creating Drug-Like Molecules
One of the remarkable achievements of DrugSynthMC is its ability to produce a large proportion of molecules that meet the desired criteria for drug development. The generated compounds are not only easy to synthesise but also soluble and non-toxic—key features for developing orally administered drugs.
The team behind this AI innovation believes that DrugSynthMC can be used to identify and refine molecules targeting proteins associated with various diseases. This could potentially lead to the discovery of novel treatments for conditions that currently have limited therapeutic options.
Their findings were published in the Journal of Chemical Information and Modeling on 9 September 2024.
A Promising Future for AI-Driven Drug Discovery
Dr Olivier Pardo, reader in cancer cell signalling at Imperial College London and co-senior author of the study, expressed his enthusiasm about the potential applications of DrugSynthMC:
“Even though this is a fairly simple algorithm, it’s far more efficient than anything more complex that has been tested or published out there and will become very useful in AI-driven drug discovery for bespoke therapeutic targets.”
One of the most promising aspects of this new tool is that it is publicly available, allowing the wider scientific community to use and build upon it. This collaborative approach could hasten progress in drug discovery, particularly in the development of treatments for diseases where current options are inadequate.
As the use of AI in drug discovery continues to grow, tools like DrugSynthMC may pave the way for faster, more efficient research, potentially leading to breakthroughs in therapeutic development for a wide range of conditions. The accessibility of this tool ensures that researchers across the globe can contribute to and benefit from this technology, propelling the field of drug discovery into a new era.
